Tag Archives: GLPG

Top 5 Warren Buffett Stocks For 2019

&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-688022858&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/688022858/960×0.jpg?fit=scale&q; data-height=&q;642&q; data-width=&q;960&q;&g; Portrait of male CEO in big corner office, looking out of window, at sunset. Photo Credit: Getty Royalty Free

&l;/p&g;&l;blockquote&g;&l;em&g;&a;ldquo;The heads of many companies are not skilled in capital allocation. Their inadequacy is not surprising because most bosses rise to the top because they have excelled in an area such as marketing, production, engineering, administration or, sometimes, institutional politics.&a;rdquo;&l;/em&g;&l;/blockquote&g;

-Warren Buffett, &l;a href=&q;http://www.berkshirehathaway.com/letters/1987.html&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;1987 letter to Berkshire Hathaway shareholders&l;/a&g;

The Oracle of Omaha observed the lack of emphasis on capital allocation over 30 years ago, and since then, it seems that little changed. A 2015 Harvard Business Review article entitled &a;ldquo;&l;a href=&q;https://hbr.org/2015/04/ceos-dont-care-enough-about-capital-allocation&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;CEO&a;rsquo;s Don&a;rsquo;t Care Enough About Capital Allocation&l;/a&g;&a;rdquo; found that hardly any top CEO&a;rsquo;s talked about return on invested capital (&l;a href=&q;https://www.newconstructs.com/education-return-on-invested-capital/&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;ROIC&l;/a&g;).

Top 5 Warren Buffett Stocks For 2019: Plexus Corp.(PLXS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Plexus Corp. (NASDAQ:PLXS) has been given an average recommendation of “Hold” by the nine brokerages that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $60.75.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Plexus (PLXS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Plexus Corp. (NASDAQ:PLXS) CAO Angelo Michael Ninivaggi, Jr. sold 6,250 shares of Plexus stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $61.79, for a total value of $386,187.50. Following the completion of the transaction, the chief accounting officer now owns 28,402 shares of the company’s stock, valued at $1,754,959.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Top 5 Warren Buffett Stocks For 2019: SPDR S&P Biotech ETF (XBI)

Advisors’ Opinion:

  • [By Jim Crumly]

    Biotech shares jumped following news of some big deals, with the SPDR S&P Biotech ETF (NYSEMKT:XBI) soaring 4.4%. Gold stocks slumped; the VanEck Vectors Gold Miners ETF (NYSEMKT:GDX) fell 1.3%. 

  • [By Shane Hupp]

    Boyer & Corporon Wealth Management LLC decreased its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 9.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 64,434 shares of the exchange traded fund’s stock after selling 6,901 shares during the quarter. SPDR S&P Biotech ETF accounts for about 2.7% of Boyer & Corporon Wealth Management LLC’s investment portfolio, making the stock its 5th largest position. Boyer & Corporon Wealth Management LLC owned approximately 0.11% of SPDR S&P Biotech ETF worth $6,133,000 as of its most recent filing with the SEC.

  • [By Jim Crumly]

    Biotech stocks made gains today, with the SPDR S&P Biotech ETF (NYSEMKT:XBI) rising 1.3%. Consumer stocks were the laggards; the Consumer Staples Select Sector SPDR ETF (NYSEMKT:XLP) fell 0.6%.

Top 5 Warren Buffett Stocks For 2019: Lawson Products Inc.(LAWS)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Lawson Products (NASDAQ:LAWS) is scheduled to announce its earnings results on Thursday, April 19th. Analysts expect the company to announce earnings of $0.16 per share for the quarter.

Top 5 Warren Buffett Stocks For 2019: Guggenheim S&P Global Water ETF (CGW)

Advisors’ Opinion:

  • [By Logan Wallace]

    Jane Street Group LLC bought a new stake in shares of Invesco S&P Global Water Index ETF (NYSEARCA:CGW) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 209,583 shares of the company’s stock, valued at approximately $7,019,000.

Top 5 Warren Buffett Stocks For 2019: Galapagos NV(GLPG)

Advisors’ Opinion:

  • [By Keith Speights]

    Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were trading 14% higher as of 11 a.m. EDT on Friday. The nice jump for the biotech stock came after Galapagos N.V. (NASDAQ:GLPG) announced disappointing results Thursday evening from a phase 2 clinical study evaluating C2 corrector GLPG2737 in treating cystic fibrosis (CF).

  • [By Cory Renauer]

    Galapagos NV (NASDAQ:GLPG) fell out of favor with a lot of investors after AbbVie (NYSE:ABBV) walked away from an important collaboration three years ago. Now that it looks like the discarded candidate could climb to the top of its class, though; the stock is more popular than ever.

  • [By Keith Speights]

    Gilead Sciences (NASDAQ:GILD) delivered some good news for its investors on Tuesday. The big biotech, along with its smaller partner, Galapagos (NASDAQ:GLPG), announced positive results from a phase 3 clinical study evaluating filgotinib in treating rheumatoid arthritis. Gilead’s share price got a nice bump from the news, while Galapagos stock skyrocketed.

Best Medical Stocks For 2019

&l;p&g;&l;img class=&q;size-full wp-image-843&q; src=&q;http://blogs-images.forbes.com/andrewrossow/files/2018/05/IMG_4209.jpg?width=960&q; alt=&q;&q; data-height=&q;623&q; data-width=&q;980&q;&g; &s;Larry King – CNN Legend &a;amp; GEAR Advisory Board member&s;

&l;span style=&q;font-weight: 400&q;&g;It is hard to imagine a world without air conditioners, vehicles or the internet. Technology has had a great impact on our world and the people who inhibit the earth today. People are living longer because technology has allowed medical research to advance. Those people are able to live anywhere in the world, in any type of housing imaginable and are able to do things that even 30 years ago seemed impossible. And technology advancements do not appear to be stopping anytime in the near future. &a;nbsp;Even though technology has advanced our capabilities and allowed us to live fuller lives, it does come with a price. &l;/span&g;

&l;span style=&q;font-weight: 400&q;&g;One of the greatest technological advances known to man was the invention of electricity. Now, hundreds of years later, almost everything we do requires electricity. And as we do more and more, we need more and more of it. Unfortunately, producing that electricity which helps us live better lives can be detrimental to the environment. Most of our electricity is generated from non-renewable sources that pollute our air and water.&l;/span&g;

Best Medical Stocks For 2019: IF Bancorp, Inc.(IROQ)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Press coverage about IF Bancorp (NASDAQ:IROQ) has trended somewhat negative on Tuesday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. IF Bancorp earned a media sentiment score of -0.01 on Accern’s scale. Accern also assigned news headlines about the savings and loans company an impact score of 46.0647914274093 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

  • [By Max Byerly]

    News stories about IF Bancorp (NASDAQ:IROQ) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. IF Bancorp earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the savings and loans company an impact score of 47.5310825195986 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

  • [By Stephan Byrd]

    Media headlines about IF Bancorp (NASDAQ:IROQ) have trended somewhat negative this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. IF Bancorp earned a daily sentiment score of -0.01 on Accern’s scale. Accern also gave news articles about the savings and loans company an impact score of 44.9246663755848 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Best Medical Stocks For 2019: Galapagos NV(GLPG)

Advisors’ Opinion:

  • [By Stephen Mack]

    Our investing experts have made some tremendous picks over the last several years, outperforming the S&P 500 by 100%, 200%, or even as much as 700% in the case of Money Morning Executive Editor Bill Patalon’s 2012 pick of Galapagos NV (Nasdaq: GLPG).

  • [By Todd Campbell, Sean Williams, and Brian Feroldi]

    There have been more stock market pops and drops lately and that might have you wondering what healthcare stocks can be bought to take advantage of this volatility. Buying healthcare stocks during periods of volatility can be smart because demand for healthcare products and services usually isn’t discretionary. However, that doesn’t necessarily mean it makes sense to buy every healthcare stock out there. To find out what healthcare stocks it might make sense to buy this month, we asked top Motley Fool investors what companies are on their radar. In their view,Teva Pharmaceutical Industries (NYSE:TEVA), Novacure (NASDAQ:NVCR), and Galapagos (NASDAQ:GLPG)should be at the top of your idea list right now. Read on to find out why.

  • [By Keith Speights]

    As icing on the cake, Gilead Sciences and partner Galapagos NV (NASDAQ:GLPG) will soon report results from a phase 3 clinical study of JAK1 inhibitor filgotinib in treating rheumatoid arthritis. If those results are positive, the biotech could be looking at peak annual sales of between $2 billion and $3 billion in the indication.

Best Medical Stocks For 2019: Luxoft Holding, Inc.(LXFT)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    Luxoft Holding (NYSE:LXFT) Q4 2018 Earnings Conference CallMay. 24, 2018 8:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Luxoft (LXFT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin]

    Luxoft Holding, Inc. (NYSE: LXFT) was down, falling around 26 percent to $32.15. Luxoft posted in-line Q4 earnings, but issued weak forecast for the current quarter.

Best Medical Stocks For 2019: Almost Family Inc(AFAM)

Advisors’ Opinion:

  • [By Max Byerly]

    Schwab Charles Investment Management Inc. boosted its position in shares of Almost Family Inc (NASDAQ:AFAM) by 12.6% during the first quarter, HoldingsChannel reports. The firm owned 62,175 shares of the company’s stock after buying an additional 6,953 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Almost Family were worth $3,482,000 at the end of the most recent reporting period.

Best Medical Stocks For 2019: Enable Midstream Partners, LP(ENBL)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Enable Midstream Partners (ENBL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Enable Midstream Partners LP (NYSE:ENBL) has been given a consensus recommendation of “Hold” by the fourteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $17.75.

  • [By Stephan Byrd]

    Enable Midstream Partners (NYSE: ENBL) and EnLink Midstream Partners (NYSE:ENLK) are both mid-cap oils/energy companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

  • [By Lee Jackson]

    Enable Midstream Partners LP (NYSE: ENBL) is raised to equal weight from underweight at Barclays. The 52-week trading range for the stock has been $12.89 to $17.67. The consensus price target is set at $17.18. The price of shares at the market’s close on Monday was $17.02.

Top 10 Blue Chip Stocks To Invest In 2019

Shutterstock

Dont take any dividends for granted today. Business disruption is accelerating as entire industries are being eaten alive.

Uber and Lyft? Killed cabs.

Amazon (AMZN)? Its crushing retail, and starving their REIT landlords right before our very eyes.

And soon, they might team up to offer more same day deliveries and make more rivals obsolete!

These types of disturbances have added a new layer to contrarian investing. Before, it was as simple as buying stocks when they were out-of-favor and holding them until they became back in vogue. The Dogs of the Dow strategy, for example, usually beat the market by banking the highest blue chip dividend yields a sign that the tide was ready to turn back in the dogs favor.

Top 10 Blue Chip Stocks To Invest In 2019: Exactech Inc.(EXAC)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Lisa Levin]

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

Top 10 Blue Chip Stocks To Invest In 2019: NEW GOLD INC.(NGD)

Advisors’ Opinion:

  • [By Paul Ausick]

    New Gold Inc. (NYSEAMERICAN: NGD) dropped about 2.9% Monday to post a new 52-week low of $2.35. Shares closed at $2.42 on Friday and the stock’s 52-week high is $4.25. Volume was about 10% below the daily average of around 5.8 million shares. The gold mining company had no news.

  • [By Dan Caplinger]

    The stock market lost ground on Monday, sending major market benchmarks lower by more than half a percentage point. The Dow lost its grip on the 20,000 mark in the wake of concerns about economic growth and new U.S. immigration policy, and some believe that the broader geopolitical climate could have a negative impact on global commerce that in turn could start affecting multinational corporations’ business prospects. In addition, bad news from some individual companies weighed on the markets, and Transocean (NYSE:RIG), Rite Aid (NYSE:RAD), and New Gold (NYSEMKT:NGD) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

  • [By Paul Ausick]

    New Gold Inc. (NYSEAMERICAN: NGD) dropped about 3.8% Thursday to post a new 52-week low of $2.28. Shares closed at $2.37 on Wednesday and the stock’s 52-week high is $4.25. Volume was about 15% below the daily average of around 5.9 million shares. The company had no specific news.

Top 10 Blue Chip Stocks To Invest In 2019: Galapagos NV(GLPG)

Advisors’ Opinion:

  • [By David Zeiler]

    Bill Patalon’s initial stock pick was Galapagos NV (Nasdaq ADR: GLPG), a Belgian biotech company.

    Patalon was attracted to Galapagos’ strategy to target “orphan diseases,” afflictions that strike rarely and so often go ignored by the Big Pharma companies. He also liked that Galapagos had more than 50 drug discovery programs underway, and that it already had licensing agreements with several bigger players in the industry.

  • [By Stephen Mack]

    Our investing experts have made some tremendous picks over the last several years, outperforming the S&P 500 by 100%, 200%, or even as much as 700% in the case of Money Morning Executive Editor Bill Patalon’s 2012 pick of Galapagos NV (Nasdaq: GLPG).

  • [By Stephen Mack]

    Galapagos NV (Nasdaq: GLPG) is our big winner so far, gaining 578.8% since Money Morning Executive Editor Bill Patalon shared his recommendation with Money Morning readers in April 2012. The S&P 500 has gained 75.4% in the same time. Bill has renewed his recommendation for the Belgian biotech several times over the years, saying in 2016 that it has “an established history of piling on gains.” With an average gain of 110% a year, it’s hard to argue with that.

Top 10 Blue Chip Stocks To Invest In 2019: lululemon athletica inc.(LULU)

Advisors’ Opinion:

  • [By Chris Lange]

    Lululemon Athletica Inc. (NASDAQ: LULU) will report its most recent quarterly results on Wednesday as well. The consensus estimates are EPS of $0.52 and $609.71 million in revenue. Shares traded at $67.22 on Friday, in a 52-week range of $47.26 to $72.70. The consensus price target is $65.50.

  • [By Chris Lange]

    Lululemon Athletica Inc. (NASDAQ: LULU) is set to release its most recent quarterly results on Tuesday. The consensus forecast calls for $1.27 in EPS and $911.42 million in revenue. Shares traded on Fridays close at $79.51. The consensus price target is $84.33, and the 52-week range is $47.26 to $83.98.

  • [By Lisa Levin]

    Shares of Lululemon Athletica inc. (NASDAQ: LULU) got a boost, shooting up 15 percent to $68.99 after the company reported stronger-than-expected earnings for its third quarter and announced a $100 million stock buyback plan.

  • [By Peter Graham]

    Athletic apparel stock Lululemon Athletica inc (NASDAQ: LULU) reported Q2 2017 earnings after the Thursday market close with results toppingexpectations as online sales surged 30% after an effort to beef up the eCommerce strategy plus the Company raised its outlook. Net revenuegrew 13% to$581.1 millionas total comparable sales increased 7% and comparable store sales increased 2%, or increased by 2% on a constant dollar basis. Direct to consumer net revenue increased 29%, or increased 30% on a constant dollar basis. During the quarter the Company held an online warehouse sale. Excluding the impact of this sale, direct to consumer net revenue increased 15%, or increased 16% on a constant dollar basis. Net income was $48.711 million versus net income of $53.625 million. The Company ended the second quarter of fiscal 2017 with $721.2 million in cash and cash equivalents compared to $535.3 million at the end of the second quarter of fiscal 2016. The CEO commented:

  • [By Paul Ausick]

    Lululemon Athletica Inc. (NASDAQ: LULU) reported fiscal second-quarter 2017 results after markets closed Thursday afternoon. The yoga gear maker reported adjusted diluted earnings per share (EPS) of $0.39 on revenues of $581.1 million, compared with EPS of $0.38 on revenues of $514.5 million in the same period a year ago. The consensus estimates called for EPS of $0.35 on revenues of $567.6 million.

  • [By Peter Graham]

    Athletic apparel stock Lululemon Athletica inc (NASDAQ: LULU)reported earnings for the first quarter ended April30, 2017along witha plan to restructure its ivivva operations. Net revenuerose 5% to$520.3 millionas total comparable sales decreased 1% whiledirect to consumer net revenue was flat. Net income was $31.246 million versus $45.336 million. In addition, the earnings report stated:

Top 10 Blue Chip Stocks To Invest In 2019: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Aimmune Therapeutics Inc (NASDAQ: AIMT) got a boost, shooting up 35 percent to $34.73 in response to failed DBVT peanut allergy trial.

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

  • [By Jim Robertson]

    Small cap clinical-stage biopharmaceutical stock Aimmune Therapeutics (NASDAQ: AIMT) is aclinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The Companys Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune Therapeutics first investigational biologic product using CODIT⒙is AR101 for the treatment of peanut allergy.AR101 has received the FDAs Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials where enrollment was announced last month.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.20, with a consensus price target of $57.11 and a 52-week range of $15.97 to $40.65.

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11

Top 10 Blue Chip Stocks To Invest In 2019: Mallinckrodt plc(MNK)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after its earnings topped the Street consensus but offered commentary that spooked investors.

    Agence France-Presse/Getty Images

    Shares of Mallinckrodt dropped 9.1% to $52.42, while the S&P 500 rose 0.1%.

    Barclays analyst Douglas Tsao and Morgan Williams callMallinckrodt’s plunge “outsized.” They explain why:

    In our view the sell-off afterMallinckrodt reported CY3Q16 earnings is outsized considering much of the disclosure on the call was largely expected, including specialty generics weakness and the 2017 outlook, which seemed relatively mild. While outsized Acthar contribution to EBITDA may be accounting for some of the sell-off, wed argue that there is benefit to the brand outperforming, especially considering the need to offset Therakos production issues in CY4Q16 and CY1Q17 as well as specialty generics weakness. We recognize some lingering headline risk associated with media reports criticizing the cost of Acthar to Medicare, after CMS released its prescription drug spending dashboard.

    Mallinckrodt’s market capitalization fell to $5.7 billion today from $6.2 billion yesterday. It reported net income of $306 million on revenue of $3.3 billion in 2015.

    This marks the third time in less than two weeks that Mallinckrodt was the S&P 500′s biggest loser.

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today as weakness that began last month even before its fourth-quarter earnings continued into year end.

    Agence France-Presse/Getty Images

    Mallinckrodtdropped 2.7% to $51.77 today, while the S&P 500 rose 0.2% to 2,268.88.

    Mallinckrodt was the biggest loser in the S&P 500 for two consecutive days in mid-November, and again after reporting its earnings.

    Mallinckrodt’s market capitalization fell to $5.5 billion today from $5.6 billion yesterday. It reported net income of $489 million on sales of $3.38 billion in fiscal 2016.

    Mallinckrodt has dropped 31% so far this year.

  • [By Johanna Bennett]

    Sell-side analysts continue to defend drug maker Mallinckrodts (MNK) shares on the heel of Citron Researchs report on the company released last week.

    Earlier today, UBS analyst Marc Goodman and his team weighed into the fray, proclaiming that a misunderstood situation creates opportunity.

    Goodman, who rates Mallinckrodt at a buy with a $92 price target, argues that Mallinckrodt is a different breed from other specialty drug makers, with high-quality earnings, sales growth fueled by volume not price hikes and an emerging pipeline we think is not just underappreciated but really not even part of the conversation with most investors.

    Also, he argues that Mallinckrodt continues to be misunderstood by investors.

    Goodman goes into goes into more detail:

    we were surprised this past week by the debate around Acthar’s Medicare exposure (~30% or ~40%), which in our view has little relevance to the overall MNK story. The key debate since the Questcor deal has been Acthar payer coverage and concerns for more barriers andor coverage blocks by the payers. There was reason for concern just 2 years ago, in our view, as several important payers increased barriers. But mgt’s aggressive focus on enhancing clinical and health-economics data to help support better coverage seems to be working and has resulted in improved coverage, which we believe is still not well appreciated.

    Mallinckrodt shares continue to climb today, rising 4.8% to a recent $57.20.

  • [By Keith Speights]

    That’s the question investors are trying to answer about how President Trump’s policies might impact healthcare stocks. So far, specific policy proposals put forward by the president appear likely to cause significant problems for certain healthcare stocks. Here’s why three of President Trump’s policies could be downright terrible for Molina Healthcare(NYSE:MOH), Mallinckrodt (NYSE:MNK), and Illumina (NASDAQ:ILMN).

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after Citron Research accused the company of fraud.

    Getty Images

    Mallinckrodt tumbled 12% to $59.60 today, while the S&P 500 declined 0.2% to 2,176.94.

    Leerink’s Jason Gerberry and Etzer Darout explain the allegations:

    Mallinckrodtshares are down -7-8% based on a short report citing CMS dashboard data which call into question Acthar Gel sales derived from government sources (CMS; Medicaid & Medicare). The report appears to overstate Acthar CMS sales as a percent of total product sales, as the methodology utilized by CMS drug spending dashboard for Medicare spend is based on gross sales, not net., although it’s unclear to what extent Acthar CMS sales are overstated.

    The report suggestsMallinckrodt mgmt understated combined Medicaid/Medicare sales on an investor call, saying it was about a little bit higher than a quarter of the business vs. gross sales on CMS dashboard implying sales were 61% of total Acthar net revenue (an apples to oranges comparison). We dont know the exact net sales of Acthar to Medicare/Medicaid, but we believe it is safe to assume Medicaid, after CPI price penalties had high discounts/rebates and assuming an 80% gross-to-net ratio on the Medicare book ($504m gross) suggests Acthar net sales would be closer to 38-45% range vs. the 61% figure cited in the short-report. Why this may matter Acthar Gel is an old product lacking good randomized, controlled data consistent with most products approved in the modern era. The report appears to be an attempt to call into question whether the government should be paying Acthars average $80-100k net price/patient/year by calling to this to the attention of government figures who have been targeting excessive drug pricing issues. This type of issue became a major headache for Mylan (MYL) investors recently with EpiPen.Mallinckrodt is presenting at a compe

Top 10 Blue Chip Stocks To Invest In 2019: Apollo Education Group, Inc.(APOL)

Advisors’ Opinion:

  • [By Peter Graham]

    The Q1 2017 earnings report for small cap for-profit education stock Apollo Education Group Inc (NASDAQ: APOL) is scheduled for after the market closes on Monday (January 9th). Last February, Apollo Education Groupannounced a definitive agreement to be acquired by a consortium of investors including The Vistria Group, LLC, funds affiliated with Apollo Global Management, LLC (NYSE: APO), and Najafi Companies for $9.50 per share in cash for both Class A and B shares. However, the for-profit education sector along with certain aspects of the Apollo deal have been targeted by the Obama administration and it remains to be seen how the Trump administration will treat the sector and the deal.

Top 10 Blue Chip Stocks To Invest In 2019: Bloomin' Brands, Inc.(BLMN)

Advisors’ Opinion:

  • [By CNBC]

    Tony Tribble, Invision/AP
    Forget about Bloomin’ Onions or boneless wings, for many consumers, the choice of where to dine often comes down to a different factor: which restaurant has the best booze.
    “Alcoholic beverages can be a key driver of traffic, differentiation, and loyalty,” said David Decker, president of Consumer Edge Insight. According to the firm, two factors that keep customers coming back are “selection” and “pricing.”
    Consumer Edge Insight recently surveyed restaurant customers to find out which casual-dining spots generated the most loyalty with their alcoholic beverages.
    Taking the top spot for “selection” was Buffalo Wild Wings (BWLD), with 29 percent of those surveyed saying they were “most likely to visit it most often due to its good selection of alcoholic beverages.”
    Applebee’s (DIN) took the second spot, with 24 percent, and Outback Steakhouse (BLMN) and T.G.I. Friday’s tied for third place with 22 percent each.
    Prices also keep customers coming back to Buffalo Wild Wings.

    When asked which casual-dining brand they were “most likely to visit most often due to its good prices of alcoholic beverages,” Buffalo Wild Wings came out on top with 30 percent. Chili’s (EAT) was No. 2 at 23 percent, and Ruby Tuesday (RT) was third with 22 percent.
    Buffalo Wild Wings has always made alcohol a part of its experience, even making it part of its tagline: “Wings.Beer.Sports.”
    The chain is the No. 1 account for more than 50 different beer brands and recently launched Game Changer, a new beer in a partnership with Redhook Brewery. Priced between cheaper domestic lagers and pricier craft beers, Game Changer became the fourth-most-popular draft beer at company-owned locations within two weeks of its release.
    “Among casual-dining restaurants, Buffalo Wild Wings is seeing the greatest positive effect in terms of building customer loyalty with its alcohol offerings,” Decker said. “There are many steps other restaurants can take to improve their alcoho

Top 10 Blue Chip Stocks To Invest In 2019: Cellect Biotechnology Ltd. (APOP)

Advisors’ Opinion:

  • [By Chris Lange]

    Cellect Biotechnology Ltd. (NASDAQ: APOP) reported that it received a formal notice from the U.S. Patent and Trademark Office (USPTO)regarding its method of treatment for immune related disorders. Basically, the USPTO gave a notice of allowance which broadly means the agency intends to issue a patent approval. The treatment method relates to the engineering of regulatory immune cells with enhanced apoptotic activity used for the treatment or prevention for the unmet needs seen in type 1 diabetes, inflammatory bowel disease, graft versus host disease, and transplant rejection.

  • [By Lisa Levin]

    Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ: APOP) shares were also up, gaining 135 percent to $7.79 after the company disclosed that it has received a notice of allowance from the US Patent Office protecting its technology in multiple key indications.

Top 10 Blue Chip Stocks To Invest In 2019: Smith & Wesson Holding Corporation(SWHC)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Sturm, Ruger & Company underperforming volatile higher flying competitors or peers like small cap gun stock American Outdoor Brands Corp (NASDAQ: AOBC), formerly Smith & Wesson Holding Corp (NASDAQ: SWHC), and electronic control device maker TASER International, Inc (NASDAQ: TASR):

  • [By Peter Graham]

    A long term performance chart shows Sturm, Ruger & Company underperforming more volatile and higher flying competitors or peers like small cap gun stock American Outdoor Brands Corp (NASDAQ: AOBC), formerly Smith & Wesson Holding Corp (NASDAQ: SWHC), and electronic control device maker Axon Enterprise (NASDAQ: AAXN), formerlyTASER International, Inc (NASDAQ: TASR):

  • [By Lisa Levin]

    Shares of Smith & Wesson Holding Corp (NASDAQ: SWHC) were down 12 percent to $21.04. Smith & Wesson reported upbeat results for its second quarter, but issued a weak outlook for its third quarter.

  • [By Peter Graham]

    A long term performance chart shows Sturm, Ruger & Company underperforming more volatile but higher flying competitors or peers like small cap gun stock American Outdoor Brands Corp (NASDAQ: AOBC), formerly Smith & Wesson Holding Corp (NASDAQ: SWHC), and electronic control device maker Axon Enterprise (NASDAQ: AAXN), formerlyTASER International, Inc (NASDAQ: TASR):

  • [By Chris Lange]

    Smith & Wesson Holding Corp. (NASDAQ: SWHC) reported fiscal second-quarter financial results after markets closed on Thursday. The company said that it had $0.68 in earnings per share (EPS) and $233.5 million in revenue, versus consensus estimates from Thomson Reuters called for $0.56 in EPS and $227.61 million in revenue. The same period from last year had $0.25 in EPS and $143.24 million in revenue.

Hot Safest Stocks To Invest In 2019

Back in my early 20s, when I was broke and in student-loan and credit-card debt, I started to be able to save a little money. Practically microscopic amounts but it was something.

I was so terrified of losing even those few dollars that I thought I needed to make them as safe as possible. So instead of putting them into vehicles that might actually make me some money, I put my funds into a savings account not even a high-yield savings account and once I started to save slightly more, into the safest mutual fund I could find, an intermediate bond fund.

Hot Safest Stocks To Invest In 2019: Galapagos NV(GLPG)

Advisors’ Opinion:

  • [By Stephen Mack]

    Our investing experts have made some tremendous picks over the last several years, outperforming the S&P 500 by 100%, 200%, or even as much as 700% in the case of Money Morning Executive Editor Bill Patalon’s 2012 pick of Galapagos NV (Nasdaq: GLPG).

  • [By Stephen Mack]

    Galapagos NV (Nasdaq: GLPG) is our big winner so far, gaining 578.8% since Money Morning Executive Editor Bill Patalon shared his recommendation with Money Morning readers in April 2012. The S&P 500 has gained 75.4% in the same time. Bill has renewed his recommendation for the Belgian biotech several times over the years, saying in 2016 that it has “an established history of piling on gains.” With an average gain of 110% a year, it’s hard to argue with that.

  • [By David Zeiler]

    Bill Patalon’s initial stock pick was Galapagos NV (Nasdaq ADR: GLPG), a Belgian biotech company.

    Patalon was attracted to Galapagos’ strategy to target “orphan diseases,” afflictions that strike rarely and so often go ignored by the Big Pharma companies. He also liked that Galapagos had more than 50 drug discovery programs underway, and that it already had licensing agreements with several bigger players in the industry.

Hot Safest Stocks To Invest In 2019: Liberty Global plc(LBTYA)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Liberty Global (NASDAQ: LBTYA) is one of 32 public companies in the “Cable & other pay television services” industry, but how does it contrast to its competitors? We will compare Liberty Global to related companies based on the strength of its institutional ownership, analyst recommendations, dividends, valuation, risk, profitability and earnings.

  • [By Alex Webb]

    Kabel Deutschland is a key part of Vodafones expansion strategy as the carrier looks for ways to boost revenue and lock in customers with Internet and television offers in addition to wireless service. Kabel Deutschland is the biggest cable company in Germany, Vodafones largest market, and had drawn a rival bid from John Malones Liberty Global Plc. (LBTYA)

Hot Safest Stocks To Invest In 2019: Navios Maritime Partners LP(NMM)

Advisors’ Opinion:

  • [By Elizabeth Balboa]

    Meanwhile, Safe Bulkers, Inc. (NYSE: SB) rose $0.73 throughout the 2016, Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) fell $1.69 and Navios Maritime Partners L.P. (NYSE: NMM) dropped $0.93.

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%

    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

Best Bank Stocks To Buy For 2018

Treasury yields rose modestly on Wednesday as the Federal Reserve delivered its first rate hike of the year, highlighting the strength of the economic outlook.

However, the central bank kept its projections for the number of rate hike this year to three instead of the more aggressive four, as some had anticipated.

What are Treasury yields doing?

The yield on the 10-year Treasury note
TMUBMUSD10Y, -0.41%
was up by 2 basis points to 2.901%, the highest since Feb. 27, while the 30-year Treasury bond yield
TMUBMUSD30Y, -0.60%
picked up 1.3 basis points to 3.126%, according to WSJ Market Data Group.

Best Bank Stocks To Buy For 2018: Lifeway Foods, Inc.(LWAY)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart for Dean Foods Co shows a positive but not spectacular long term return as small cap Lifeway Foods, Inc (NASDAQ: LWAY) has been more volatile and non-dairy desert stock Tofutti Brands Inc (NYSEMKT: TOF) has given a moderately positive performance:

  • [By Jim Robertson]

    Last Friday, our Under the Radar Moversnewsletter suggested shorting small capdairy health food product stock Lifeway Foods, Inc (NASDAQ: LWAY):

Best Bank Stocks To Buy For 2018: lululemon athletica inc.(LULU)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Athleisure apparel company Lululemon (LULU) , reeling from a 23% drop in its stock price last week, has added a veteran of publicly-traded retailers to its board.

  • [By Chris Lange]

    Lululemon Athletica Inc. (NASDAQ: LULU) is set to release its most recent quarterly results on Tuesday. The consensus forecast calls for $1.27 in EPS and $911.42 million in revenue. Shares traded on Fridays close at $79.51. The consensus price target is $84.33, and the 52-week range is $47.26 to $83.98.

  • [By Peter Graham]

    Athletic apparel stock Lululemon Athletica inc (NASDAQ: LULU)reported earnings for the first quarter ended April30, 2017along witha plan to restructure its ivivva operations. Net revenuerose 5% to$520.3 millionas total comparable sales decreased 1% whiledirect to consumer net revenue was flat. Net income was $31.246 million versus $45.336 million. In addition, the earnings report stated:

  • [By ]

    First up is Lululemon Athletica (NASDAQ:LULU). LULU makes high-end yoga gear and other athletic apparel.

    Of course, workout clothes arent just for the gym anymore. The athleisure segment has exploded over the past ten years. The sports apparel and footwear market has grown 42% since 2009 to $270 billion, according to Morgan Stanley. Analysts are guessing it will grow another 30% before the decade is over.

Best Bank Stocks To Buy For 2018: Galapagos NV(GLPG)

Advisors’ Opinion:

  • [By Stephen Mack]

    Our investing experts have made some tremendous picks over the last several years, outperforming the S&P 500 by 100%, 200%, or even as much as 700% in the case of Money Morning Executive Editor Bill Patalon’s 2012 pick of Galapagos NV (Nasdaq: GLPG).

  • [By Stephen Mack]

    Galapagos NV (Nasdaq: GLPG) is our big winner so far, gaining 578.8% since Money Morning Executive Editor Bill Patalon shared his recommendation with Money Morning readers in April 2012. The S&P 500 has gained 75.4% in the same time. Bill has renewed his recommendation for the Belgian biotech several times over the years, saying in 2016 that it has “an established history of piling on gains.” With an average gain of 110% a year, it’s hard to argue with that.

  • [By David Zeiler]

    Bill Patalon’s initial stock pick was Galapagos NV (Nasdaq ADR: GLPG), a Belgian biotech company.

    Patalon was attracted to Galapagos’ strategy to target “orphan diseases,” afflictions that strike rarely and so often go ignored by the Big Pharma companies. He also liked that Galapagos had more than 50 drug discovery programs underway, and that it already had licensing agreements with several bigger players in the industry.